Serum fibrosis markers can predict rapid fibrosis progression after liver transplantation for hepatitis C
Surakit Pungpapong, David P. Nunes, Murli Krishna, Raouf Nakhleh, Kyle Chambers, Marwan Ghabril, Rolland C. Dickson, Christopher B. Hughes, Jeffery Steers, Justin H. Nguyen, Andrew P. Keaveny – 28 August 2008 – Although recurrent hepatitis C virus (HCV) after liver transplantation (LT) is universal, a minority of patients will develop cirrhosis within 5 years of surgery, which places them at risk for allograft failure.